All In Biotech

Drug Trial Radar · NCT02150967

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy

Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

143

Actual

Start

Jul 23, 2014

Primary completion

Mar 1, 2021

Study completion Feb 7, 2022

Sponsor

Sponsor type
Industry
Collaborators
Helsinn Healthcare SA
First posted
May 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open label, single arm phase II study evaluating BGJ398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (FGFR) genetic alterations.

Conditions

  • Advanced Cholangiocarcinoma
  • FGFR2 Gene Mutation

Interventions

  • BGJ398 (infigratinib)Drug

    Capsule for oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) as Assessed by Blinded Independent Central Imaging Review (BICR)Time frame: Analysis was conducted when all subjects in Cohort 1 had the opportunity to be followed for at least 10 months after their initial exposure to infigratinib. Data cutoff 01 March 2021.

Locations

37 sites in 11 countries. Site status is shown where the registry gives one.

  • QED Investigative Site

    Phoenix, Arizona

  • QED Investigative Site

    Los Angeles, California

  • QED Investigative Site

    Los Angeles, California

  • QED Investigative Site

    San Francisco, California

  • QED Investigative Site

    Boston, Massachusetts

  • QED Investigative Site

    Detroit, Michigan

  • QED Investigative Site

    New York, New York

  • QED Investigative Site

    New York, New York

  • QED Investigative Site

    New York, New York

  • QED Investigative Site

    Columbus, Ohio

  • QED Investigative Site

    Houston, Texas

  • QED Investigative Site

    Brussels, Belgium

  • QED Investigative Site

    Leuven, Belgium

  • QED Investigative Site

    Heidelberg, Germany

  • QED Investigative Site

    Tübingen, Germany

  • QED Investigative Site

    Cologne, North Rhine-Westphalia, Germany

  • QED Investigative Site

    Ancona, AN, Italy

  • QED Investigative Site

    Milan, MI, Italy

  • QED Investigative Site

    Roma, RM, Italy

  • QED Investigative Site

    Moscow, Russia

  • QED Investigative Site

    Volzhskiy, Russia

  • QED Investigative Site

    Singapore, Singapore

  • QED Investigative Site

    Singapore, Singapore

  • QED Investigative Site

    Seoul, Korea, South Korea

  • QED Investigative Site

    Seoul, Korea, South Korea

  • QED Investigative Site

    Barcelona, Spain

  • QED Investigative Site

    Barcelona, Spain

  • QED Investigative Site

    Madrid, Spain

  • QED Investigative Site

    Zhunan, Taiwan

  • QED Investigative Site

    Taipei, Taiwan ROC, Taiwan

  • QED Investigative Site

    Bangkok, Thailand

  • QED Investigative Site

    Bangkok, Thailand

  • QED Investigative Site

    Khon Kaen, THA, Thailand

  • QED Investigative Site

    Bebington, United Kingdom

  • QED Investigative Site

    Birmingham, United Kingdom

  • QED Investigative Site

    Manchester, United Kingdom

  • QED Investigative Site

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.